Optimization of protein encapsulation in PLGA nanoparticles

Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and release

“…In many studies to date, the influence of changing numerous process parameters -such as the amount of polymer and drug used, the time for preparation, and the selected excipients (different emulsifier or release modifier) -on particles produced via the double emulsion method has been described (Buske et al, 2012;Corrigan and Li, 2009;Cruz et al, 2011;Feczkó et al, 2011;Mundargi et al, 2008). However, for comparison of the potential of a polymer to act as an encapsulation material it is of utmost importance to keep the majority of process parameters unchanged.…”

A Multioptimization Approach to Assessment of Drug Delivery of PLGA Nanoparticles: Simultaneous Control of Particle Size and Release Behavior

“…To accomplish such purpose, numerous researchers have focused on preparing drug-loaded PLGA particles and investigating the effect of different process parameters on the characteristics of resulting systems [6,[11][12][13][14][15][16][17]. To identify and control critical source of variability in the process and understand the impact of formulation components and process parameters on the critical quality attributes, some performed experimental design and analysis [18][19][20][21][22][23][24][25][26][27][28][29][30]. In a recent study, drug-loaded PLGA particles were prepared by the double emulsion solvent evaporation method and albumin-fluorescein isothiocyanate conjugate (FITC-albumin) was used as a model drug.…”

In Vitro IFN-α Release From IFN-α- and Pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and Pegylated poly(lactic-co-glycolic acid) Nanoparticles

“…It is also emphasized that there is a long development and improving work behind the results of the present study. Some of our previous and recent papers [10][11][12][13][14][15] contain the most important achievements during the optimization of size and encapsulation efficiency of PLGA nanoparticles containing model proteins, while the properties of magnetic PLGA nanoparticles with the IFN-α active agent were initially improved in a PhD thesis [16]. In the present study we used all of the knowledge obtained during the almost 10-year development of PLGA nanoparticles to produce optimal interferon alpha containing nanoparticles.…”